12,372 trials
Growth Hormone Deficiency
Primary: Percentage of Dyads (Participant and Caregiver or Parent) and Adult Participants Reporting no Difference or Easier to Use for the New Genotropin Mark VII Injection Pen…
Newly Diagnosed Multiple Myeloma
Primary: Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC) — 136.1; 62.1; 56.1 weeks — p=<0.001
Antithrombin III Deficiency
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT) — 0 Participants
Heart Decompensation
Primary: Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality — 321; 345 Participants — p=0.313
Infections, Papillomavirus
Primary: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN1+) and/or Persistent Infection (6 Month+ Definition) Associated With Human…
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Antibody Concentrations Against Pneumococcal Vaccine Serotypes — 2.13; 3.04; 3.24; 1.32 microgram per milliliter
Atrial Fibrillation
Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001
Dental Caries
Primary: Number of Caries Incident Cases — 42; 23; 14 participants — p=<0.001
Migraine, Acute
Primary: Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age — 87; 63; 197; 223 participants — p=0.025
Alzheimer's Disease
Primary: Sensitivity Analysis in All Autopsy Population — 36; 3 participants
Chronic Obstructive Pulmonary Disease
Primary: Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks (Day 21) of Treatment — 505.63; 416.70 seconds
Alzheimer's Disease
Primary: Correlation of Florbetapir-PET Image and Amyloid Plaque Density — 0.78 Correlation coefficient — p=<0.0001
Depression · Depressive Disorder · Depressive Disorder, Major
Primary: Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8. — -12.64; -8.33 units on scale — p=<0.001
Neuromuscular Blockade
Primary: Time From Start of Study Drug Administration to Recovery of the T4/T1 Ratio to 0.9 — 1.77; 14.80 minutes — p=<0.0001
Paget's Disease of Bone
Primary: Number of Patients Who Achieve Therapeutic Response at 6 Months. — 85; 60 participants